JP6383783B2 - インプラントの表面処理方法 - Google Patents
インプラントの表面処理方法 Download PDFInfo
- Publication number
- JP6383783B2 JP6383783B2 JP2016511664A JP2016511664A JP6383783B2 JP 6383783 B2 JP6383783 B2 JP 6383783B2 JP 2016511664 A JP2016511664 A JP 2016511664A JP 2016511664 A JP2016511664 A JP 2016511664A JP 6383783 B2 JP6383783 B2 JP 6383783B2
- Authority
- JP
- Japan
- Prior art keywords
- implant
- acid
- surface treatment
- factor
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007943 implant Substances 0.000 title claims description 126
- 238000004381 surface treatment Methods 0.000 title claims description 91
- 238000000034 method Methods 0.000 title claims description 51
- 239000000203 mixture Substances 0.000 claims description 57
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 26
- 238000001035 drying Methods 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 16
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- 239000007995 HEPES buffer Substances 0.000 claims description 12
- 229920002971 Heparan sulfate Polymers 0.000 claims description 12
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 claims description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 12
- 239000008103 glucose Substances 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 9
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 9
- -1 dextran sulfate Polymers 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 8
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 8
- 239000010936 titanium Substances 0.000 claims description 8
- 229910052719 titanium Inorganic materials 0.000 claims description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 claims description 6
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 claims description 6
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 claims description 6
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims description 6
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 claims description 6
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- 229920002101 Chitin Polymers 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 claims description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 6
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 claims description 6
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 claims description 6
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 6
- 150000007513 acids Chemical class 0.000 claims description 6
- 235000010443 alginic acid Nutrition 0.000 claims description 6
- 229920000615 alginic acid Polymers 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 229940045110 chitosan Drugs 0.000 claims description 6
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000011368 organic material Substances 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 229910001069 Ti alloy Inorganic materials 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 235000009582 asparagine Nutrition 0.000 claims description 5
- 229960001230 asparagine Drugs 0.000 claims description 5
- 239000001506 calcium phosphate Substances 0.000 claims description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 5
- 235000011010 calcium phosphates Nutrition 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 5
- 235000006109 methionine Nutrition 0.000 claims description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 5
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 claims description 4
- 108010003541 Platelet Activating Factor Proteins 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 3
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 3
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 claims description 3
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 3
- 239000007991 ACES buffer Substances 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- 229920000856 Amylose Polymers 0.000 claims description 3
- 108010001779 Ancrod Proteins 0.000 claims description 3
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- 108010027612 Batroxobin Proteins 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 229920002567 Chondroitin Polymers 0.000 claims description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 3
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 229920002558 Curdlan Polymers 0.000 claims description 3
- 239000001879 Curdlan Substances 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 108010014258 Elastin Proteins 0.000 claims description 3
- 102000016942 Elastin Human genes 0.000 claims description 3
- 108010076282 Factor IX Proteins 0.000 claims description 3
- 108010048049 Factor IXa Proteins 0.000 claims description 3
- 108010023321 Factor VII Proteins 0.000 claims description 3
- 108010054265 Factor VIIa Proteins 0.000 claims description 3
- 108010014173 Factor X Proteins 0.000 claims description 3
- 108010074864 Factor XI Proteins 0.000 claims description 3
- 108010080865 Factor XII Proteins 0.000 claims description 3
- 102000000429 Factor XII Human genes 0.000 claims description 3
- 108010071241 Factor XIIa Proteins 0.000 claims description 3
- 108010080805 Factor XIa Proteins 0.000 claims description 3
- 108010074860 Factor Xa Proteins 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- 108010049003 Fibrinogen Proteins 0.000 claims description 3
- 102000008946 Fibrinogen Human genes 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 102000016359 Fibronectins Human genes 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 229920002527 Glycogen Polymers 0.000 claims description 3
- 239000006173 Good's buffer Substances 0.000 claims description 3
- 239000007996 HEPPS buffer Substances 0.000 claims description 3
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 claims description 3
- 108010022901 Heparin Lyase Proteins 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229920000288 Keratan sulfate Polymers 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 239000007993 MOPS buffer Substances 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 claims description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 claims description 3
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 claims description 3
- 239000007990 PIPES buffer Substances 0.000 claims description 3
- 108010077971 Plasminogen Inactivators Proteins 0.000 claims description 3
- 102000010752 Plasminogen Inactivators Human genes 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 3
- 108010094028 Prothrombin Proteins 0.000 claims description 3
- 102100027378 Prothrombin Human genes 0.000 claims description 3
- 239000004373 Pullulan Substances 0.000 claims description 3
- 229920001218 Pullulan Polymers 0.000 claims description 3
- 102000003800 Selectins Human genes 0.000 claims description 3
- 108090000184 Selectins Proteins 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 108090000190 Thrombin Proteins 0.000 claims description 3
- 108010000499 Thromboplastin Proteins 0.000 claims description 3
- 102000002262 Thromboplastin Human genes 0.000 claims description 3
- 239000007997 Tricine buffer Substances 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 3
- 102000002852 Vasopressins Human genes 0.000 claims description 3
- 108010004977 Vasopressins Proteins 0.000 claims description 3
- 238000010306 acid treatment Methods 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 229920013820 alkyl cellulose Polymers 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 229960004233 ancrod Drugs 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960002210 batroxobin Drugs 0.000 claims description 3
- 239000007998 bicine buffer Substances 0.000 claims description 3
- 239000006177 biological buffer Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 229920003064 carboxyethyl cellulose Polymers 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 3
- 229940107200 chondroitin sulfates Drugs 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229940078035 curdlan Drugs 0.000 claims description 3
- 235000019316 curdlan Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 229960002086 dextran Drugs 0.000 claims description 3
- 229960000633 dextran sulfate Drugs 0.000 claims description 3
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 claims description 3
- 108010085662 ecarin Proteins 0.000 claims description 3
- 229920002549 elastin Polymers 0.000 claims description 3
- 229960005139 epinephrine Drugs 0.000 claims description 3
- 229960004222 factor ix Drugs 0.000 claims description 3
- 229940012413 factor vii Drugs 0.000 claims description 3
- 229940012414 factor viia Drugs 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 229940012952 fibrinogen Drugs 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229940014259 gelatin Drugs 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 229960002442 glucosamine Drugs 0.000 claims description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims description 3
- 229940096919 glycogen Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910001510 metal chloride Inorganic materials 0.000 claims description 3
- 229910001960 metal nitrate Inorganic materials 0.000 claims description 3
- 229910001463 metal phosphate Inorganic materials 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- 229960000292 pectin Drugs 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 238000009832 plasma treatment Methods 0.000 claims description 3
- 239000002797 plasminogen activator inhibitor Substances 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000003805 procoagulant Substances 0.000 claims description 3
- 235000013930 proline Nutrition 0.000 claims description 3
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims description 3
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 3
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 3
- 229940039716 prothrombin Drugs 0.000 claims description 3
- 235000019423 pullulan Nutrition 0.000 claims description 3
- 229940107700 pyruvic acid Drugs 0.000 claims description 3
- 235000004400 serine Nutrition 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- YCLWMUYXEGEIGD-UHFFFAOYSA-M sodium;2-hydroxy-3-[4-(2-hydroxyethyl)piperazin-1-yl]propane-1-sulfonate Chemical compound [Na+].OCCN1CCN(CC(O)CS([O-])(=O)=O)CC1 YCLWMUYXEGEIGD-UHFFFAOYSA-M 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 229910052712 strontium Inorganic materials 0.000 claims description 3
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- 229960004072 thrombin Drugs 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 229960003726 vasopressin Drugs 0.000 claims description 3
- 239000002435 venom Substances 0.000 claims description 3
- 210000001048 venom Anatomy 0.000 claims description 3
- 231100000611 venom Toxicity 0.000 claims description 3
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 3
- 102100036537 von Willebrand factor Human genes 0.000 claims description 3
- 229960001134 von willebrand factor Drugs 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000011343 solid material Substances 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 238000007781 pre-processing Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000007789 sealing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012805 post-processing Methods 0.000 description 3
- HOZBSSWDEKVXNO-BXRBKJIMSA-N (2s)-2-azanylbutanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O HOZBSSWDEKVXNO-BXRBKJIMSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 229910001410 inorganic ion Inorganic materials 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- DHEQXMRUPNDRPG-UHFFFAOYSA-N strontium nitrate Chemical compound [Sr+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O DHEQXMRUPNDRPG-UHFFFAOYSA-N 0.000 description 2
- UBXAKNTVXQMEAG-UHFFFAOYSA-L strontium sulfate Chemical compound [Sr+2].[O-]S([O-])(=O)=O UBXAKNTVXQMEAG-UHFFFAOYSA-L 0.000 description 2
- 125000000542 sulfonic acid group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- YNLCVAQJIKOXER-UHFFFAOYSA-N N-[tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid Chemical compound OCC(CO)(CO)NCCCS(O)(=O)=O YNLCVAQJIKOXER-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- CPSYWNLKRDURMG-UHFFFAOYSA-L hydron;manganese(2+);phosphate Chemical compound [Mn+2].OP([O-])([O-])=O CPSYWNLKRDURMG-UHFFFAOYSA-L 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- BDAGIHXWWSANSR-NJFSPNSNSA-N hydroxyformaldehyde Chemical compound O[14CH]=O BDAGIHXWWSANSR-NJFSPNSNSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011656 manganese carbonate Substances 0.000 description 1
- 235000006748 manganese carbonate Nutrition 0.000 description 1
- 229940093474 manganese carbonate Drugs 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- MIVBAHRSNUNMPP-UHFFFAOYSA-N manganese(2+);dinitrate Chemical compound [Mn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MIVBAHRSNUNMPP-UHFFFAOYSA-N 0.000 description 1
- 229910000016 manganese(II) carbonate Inorganic materials 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005488 sandblasting Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910000018 strontium carbonate Inorganic materials 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- JOPDZQBPOWAEHC-UHFFFAOYSA-H tristrontium;diphosphate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O JOPDZQBPOWAEHC-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/06—Titanium or titanium alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D3/00—Pretreatment of surfaces to which liquids or other fluent materials are to be applied; After-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
- B05D3/007—After-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0012—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the material or composition, e.g. ceramics, surface layer, metal alloy
- A61C8/0013—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the material or composition, e.g. ceramics, surface layer, metal alloy with a surface layer, coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dentistry (AREA)
- Materials For Medical Uses (AREA)
- Dental Prosthetics (AREA)
Description
前記インプラントはチタンまたは、チタン合金を含むことができる。
(実施例)
<実施例1〜3:インプラントの表面前処理および後処理>
先に、UV装置(アテク、AH−1700)を利用してチタンインプラント(自体製作)の表面にUVを1時間照射した(これを「前処理」という)。以後、下記表1の表面処理用組成物10μlを前記前処理されたインプラントの表面に塗布した後、前記表面処理用組成物で塗布されたインプラントを、25℃で20分、その後60℃で2時間乾燥した(これを「後処理」という)。
UV装置(アテク、AH−1700)を利用してチタンインプラント(自体製作)の表面にUVを1時間照射して前記インプラントの表面を前処理した。しかし、前記前処理されたインプラントの表面に表面処理用組成物を塗布および乾燥する段階(すなわち、後処理段階)は省略した。
(評価例)
<評価例1:インプラント表面の色評価>
前記比較例1で前処理だけを行ったインプラントの表面写真と前記実施例1〜3で前処理と後処理をすべて行ったインプラントの表面写真を撮影して、その結果を図1に示した。
<評価例2:インプラント表面の血液親和度評価>
前記比較例1で前処理のみを行ったインプラントと前記実施例1〜3で前処理と後処理をすべて行ったインプラントを人体血液に浸漬して取り出した後、前記各インプラントの写真を撮影して、その結果を図2に示した。
<評価例3:表面処理用組成物のシミ特性評価>
インプラントの表面処理用組成物のうち、生理食塩水が含まれているかの可否およびグルコースの濃度によるインプラントの表面状態を示している写真を撮影して、その結果を図3に示した。ここで、生理食塩水が含まれていない表面処理用組成物の製造およびインプラントの表面処理は、実施例1と同じ方法(ただし、グルコースの濃度は変化する)で実施し、生理食塩水が含まれている表面処理用組成物の製造およびインプラントの表面処理は、実施例2と同じ方法(ただし、グルコースの濃度は変化する)で実施した。
<評価例4:表面処理用組成物の乾燥特性評価>
インプラントの表面処理用組成物のうち、HEPESおよび/または、生理食塩水が含まれているかの可否によるインプラントの表面状態を示す写真を撮影して、その結果を図4に示した。図4の各場合に下記の表面処理用組成物を用いたことを除いては、実施例1〜3と同じ方法でそれぞれのチタンインプラントを前処理および後処理を施した。
Claims (15)
- 親水性基含有有機物を含む表面処理用組成物をインプラントの表面に塗布する段階(塗布段階)と、
前記塗布された表面処理用組成物を乾燥する段階(乾燥段階)とを含み、
前記表面処理用組成物は、無機塩を含み、
前記表面処理用組成物のうち、前記無機塩の濃度は200mM以下であり、
前記無機塩は、前記乾燥段階において、前記表面処理用組成物が塗布された前記インプラントの表面全体を均一な速度で乾燥させて、
前記乾燥段階により、前記インプラントの表面に固形物質(前記親水性基含有有機物および前記無機塩)が残留する、インプラントの表面処理方法。 - 前記塗布段階前に前記インプラントの表面を前処理する段階(前処理段階)をさらに含む、請求項1に記載のインプラントの表面処理方法。
- 前記前処理段階は、サンドブラスト処理、リン酸カルシウムコーティング、UV処理、プラズマ処理、酸処理および塩基処理中の少なくとも一つの操作によって行われる、請求項2に記載のインプラントの表面処理方法。
- 前記親水性基は、ヒドロキシル基(OH)、カルボキシル基(COOH)、アミノ基(NH2)およびスルホン酸基(−SO3H)からなる群より選択された少なくとも一つを含む、請求項1に記載のインプラントの表面処理方法。
- 前記有機物は、糖類(saccharides)、蛋白質類(proteins)、酸類(acids)および生理的緩衝溶液(biologicalbuffer or good'sbuffer)からなる群より選択された少なくとも一つを含む、請求項1に記載のインプラントの表面処理方法。
- 前記糖類は、グルコース、セルロース、アルキルセルロース、アルキルヒドロキシアルキルセルロース、ヒドロキシアルキルセルロース、セルロースサルフェート、カルボキシメチルセルロースの塩、カルボキシメチルセルロース、カルボキシエチルセルロース、キチン、カルボキシメチルキチン、ヒアルロン酸、ヒアルロン酸の塩、アルギネート、アルギン酸、プロピレングリコールアルギネート、グリコーゲン、デキストラン、デキストランサルフェート、カードラン(curdlan)、ペクチン、プルラン、キサンタン、コンドロイチン(chondroitin)、コンドロイチンサルフェート類、カルボキシメチルデキストラン、カルボキシメチルキトサン、キトサン、ヘパリン、ヘパリンサルフェート、ヘパラン(heparan)、ヘパランサルフェート、デルマタンサルフェート、ケラタンサルフェート、カラギーナン、澱粉、アミロース、アミロベクチン、ポリ−N−グルコサミン、ポリマンヌロン酸(polymannuronic acid)、ポリグルクロン酸(polyglucuronic acid)、ポリグルロン酸(polyguluronicacid)および前記糖類の誘導体からなる群より選択された少なくとも一つを含む、請求項5に記載のインプラントの表面処理方法。
- 前記蛋白質は、ゼラチン、プロトロンビン、トロンビン、フィブリノーゲン、フィブリン、フィブロネクチン、ヘパリナーゼ、X因子、Xa因子、VII因子、VIIa因子、IX因子、IXa因子、XI因子、XIa因子、XII因子、XIIa因子、組織因子、バトロキソビン(batroxobin)、アンクロッド(ancrod)、エカリン(ecarin)、フォンヴィルブランド因子(von Willebrand Factor)、コラーゲン、エラスチン、アルブミン、血小板表面糖蛋白質(platelet surface glycoproteins)、バソプレシン(vasopressin)、バソプレシンアナログ(vasopressin analogs)、エピネフリン(epinephrine)、セレクチン(selectin)、凝血促進性毒(procoagulant venom)、プラスミノーゲン活性化因子抑制剤(plasminogen activator inhibitor)、血小板活性化因子(plateletactivatingfactor)およびペプチドからなる群より選択された少なくとも一つを含む、請求項5に記載のインプラントの表面処理方法。
- 前記酸類は、ピルビン酸(pyruvic acid)、乳酸(lactic acid)、システイン(cysteine)、グルタミン(glutamine)、チロシン(tyrosine)、ロイシン(leucine)、リシン(lysine)、バリン(valine)、イソロイシン(isoleucine)、スレオニン(threonine)、フェニルアラニン(phenylalanine)、トリプトファン(tryptophan)、ヒスチジン(histidine)、アルギニン(arginine)、グリシン(グリシン)、セリン(serine)、プロリン(proline)、グルタミン酸(glutamic acid)、アスパラギン酸(aspartic acid)、アラニン(alanine)、メチオニン(methionine)およびアスパラギン(asparagine)からなる群より選択された少なくとも一つを含む、請求項5に記載のインプラントの表面処理方法。
- 前記生理的緩衝溶液は、MES(2−(N−モルホリノ)エタンスルホン酸)、ADA(N−(カルバモイルメチル)イミノジ酢酸)、PIPES(1、4−ピペラジンジエタンスルホン酸)、ACES(2−(カルバモイルメチルアミノ)エタンスルホン酸)、MOPSO(3−モルホリノ−2−ヒドロキシプロパンスルホン酸)、コールアミンクロライド(cholamine chloride)、MOPS(3−モルホリノプロパン−1−スルホン酸)、BES(N、N−ビス(2−ヒドロキシエチル)−2−アミノエタンスルホン酸)、TES(2−[[1、3−ジヒドロキシ−2−(ヒドロキシメチル)プロパン−2−イル]アミノ]エタンスルホン酸)、HEPES(2−[4−(2−ヒドロキシエチル)ピペラジン−1−イル]エタンスルホン酸)、DIPSO(3−(N、N−ビス[2−ヒドロキシエチル]アミノ)−2−ヒドロキシプロパンスルホン酸)、アセトアミドグリシン(acetamido glycine)、TAPSO(3−[[1、3−ジヒドロキシ−2−(ヒドロキシメチル)プロパン−2−イル]アミノ]−2−ヒドロキシプロパン−1−スルホン酸)、HEPPSO(N−(2−ヒドロキシエチル)ピペラジン−N’−(2−ヒドロキシプロパンスルホン酸)、HEPPS(4−(2−ヒドロキシエチル)−ピペラジン−1−プロパンスルホン酸)、トリシン(N−(2−ヒドロキシ−1、1−ビス(ヒドロキシメチル)エチル)グリシン)、グリシンアミド(glycinamide)、ビシン(2−ビス(2−ヒドロキシエチル)アミノ)酢酸)およびTAPS(3−[[1、3−ジヒドロキシ−2−(ヒドロキシメチル)プロパン−2−イル]アミノ]プロパン−1−スルホン酸)からなる群より選択された少なくとも一つを含む、請求項5に記載のインプラントの表面処理方法。
- 前記表面処理用組成物のうち前記有機物の濃度は2000mM以下である、請求項1に記載のインプラントの表面処理方法。
- 前記無機塩は、金属塩化物、金属リン酸塩、金属硫酸塩、金属炭酸塩および金属硝酸塩からなる群より選択された少なくとも一つを含む、請求項1に記載のインプラントの表面処理方法。
- 前記無機塩中の金属は、ナトリウム、カルシウム、カリウム、ストロンチウム、マンガンおよびマグネシウムからなる群より選択された少なくとも一つを含む、請求項11に記載のインプラントの表面処理方法。
- 前記表面処理用組成物は水溶液の形態である、請求項1に記載のインプラントの表面処理方法。
- 前記インプラントはチタンまたは、チタン合金を含む、請求項1に記載のインプラントの表面処理方法。
- 前記乾燥段階は200℃以下の温度で行われる、請求項1に記載のインプラントの表面処理方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0049617 | 2013-05-02 | ||
KR20130049617A KR101404632B1 (ko) | 2013-05-02 | 2013-05-02 | 임플란트의 표면처리방법 |
PCT/KR2013/008525 WO2014178489A1 (ko) | 2013-05-02 | 2013-09-24 | 임플란트의 표면처리방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016522026A JP2016522026A (ja) | 2016-07-28 |
JP6383783B2 true JP6383783B2 (ja) | 2018-08-29 |
Family
ID=51132104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016511664A Active JP6383783B2 (ja) | 2013-05-02 | 2013-09-24 | インプラントの表面処理方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US10786602B2 (ja) |
EP (1) | EP2992908B1 (ja) |
JP (1) | JP6383783B2 (ja) |
KR (1) | KR101404632B1 (ja) |
CN (1) | CN105339017B (ja) |
DK (1) | DK2992908T3 (ja) |
ES (1) | ES2828063T3 (ja) |
HU (1) | HUE051263T2 (ja) |
PT (1) | PT2992908T (ja) |
WO (1) | WO2014178489A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210020836A (ko) * | 2019-08-14 | 2021-02-24 | (주)네이처글루텍 | 홍합접착단백질로 코팅된 치과용 임플란트 |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101460976B1 (ko) | 2014-07-11 | 2014-11-13 | 오스템임플란트 주식회사 | 표면이 코팅되어 생체 친화성이 향상된 치과용 임플란트 및 이의 제조 방법 |
KR101460973B1 (ko) | 2014-07-11 | 2014-11-13 | 오스템임플란트 주식회사 | 표면이 코팅되어 생체 친화성과 생체 적합성이 향상된 치과용 임플란트 및 이의 제조 방법 |
KR101460974B1 (ko) | 2014-07-11 | 2014-11-13 | 오스템임플란트 주식회사 | 표면이 코팅되어 생체 적합성이 향상된 치과용 임플란트 및 이의 제조 방법 |
WO2016006889A1 (ko) * | 2014-07-11 | 2016-01-14 | 오스템임플란트 주식회사 | 표면이 코팅되어 생체 친화성과 생체 적합성이 향상된 치과용 임플란트 및 이의 제조방법 |
EP3034033A1 (en) | 2014-12-16 | 2016-06-22 | Nobel Biocare Services AG | Dental implant |
CN106011834B (zh) * | 2016-06-12 | 2018-12-04 | 天津大学 | 钛表面螯合锶的海藻酸钠涂层的制备方法 |
CN106581769A (zh) * | 2016-12-09 | 2017-04-26 | 苏州纳贝通环境科技有限公司 | 一种功能化纳米生物陶瓷涂层及其制备工艺 |
CN106983908A (zh) * | 2017-03-03 | 2017-07-28 | 吕亚林 | 用于长期抗血小板药物治疗患者的特异性种植体及其制作方法 |
US11540866B2 (en) | 2017-03-29 | 2023-01-03 | Bone Solutions, Inc. | Implant of osteostimulative material |
WO2018189185A1 (en) | 2017-04-11 | 2018-10-18 | Straumann Holding Ag | Dental implant |
CN107185055B (zh) * | 2017-04-28 | 2019-12-31 | 淮阴工学院 | 一种医用镁合金的表面改性方法 |
CN107260342A (zh) * | 2017-06-30 | 2017-10-20 | 青岛大学附属医院 | 一种3d打印仿生牙种植体及其制作方法 |
JP7234222B2 (ja) * | 2017-10-06 | 2023-03-07 | ディーエスエム アイピー アセッツ ビー.ブイ. | 骨伝導性繊維状物品の製造方法及びかかる骨伝導性繊維状物品を含む医療用インプラント |
US20190125420A1 (en) * | 2017-10-31 | 2019-05-02 | Bone Solutions, Inc. | Bioabsorbable Composite Screw |
CN108478298B (zh) * | 2018-03-01 | 2020-11-10 | 澳门大学 | 一种含有可结合生长因子的多糖涂层的种植体及其制备方法 |
CN109125790A (zh) * | 2018-08-25 | 2019-01-04 | 山东康力医疗器械科技有限公司 | 一种采用壳聚糖制作的止血海绵结构 |
KR102081619B1 (ko) * | 2019-01-16 | 2020-02-26 | 주식회사 씨에스와이 | 인시츄(In-situ) 공정을 이용한 치과용 임플란트 픽스쳐의 표면처리 방법 |
KR102148868B1 (ko) | 2019-01-16 | 2020-08-28 | 주식회사 씨에스와이 | 개선된 공정 및 식각액을 이용한 치과용 임플란트 픽스쳐의 표면처리 방법 |
KR101972122B1 (ko) * | 2019-01-31 | 2019-04-24 | 주식회사 네오바이오텍 | 표면 형태학적 특성 및 골 유착성이 개선된 치과용 임플란트의 제조방법 |
US20220168467A1 (en) * | 2019-03-19 | 2022-06-02 | Qvanteq Ag | Medical device and process of preparing a medical device |
KR102344959B1 (ko) | 2019-12-06 | 2021-12-28 | 영산대학교산학협력단 | 로즈마리 추출물을 포함하는 임플란트의 골유착 개선용 조성물 |
CN111744055A (zh) * | 2020-06-29 | 2020-10-09 | 北京星云中御科技有限公司 | 一种亲水性种植体产品和其制备方法 |
KR20220090934A (ko) | 2020-12-23 | 2022-06-30 | 수바이오 주식회사 | 친수성 표면을 갖는 임플란트의 제조방법 및 상기 방법으로 제조된 임플란트 |
JP7083557B1 (ja) * | 2020-12-25 | 2022-06-13 | 株式会社エー・アイ・システムプロダクト | チタン又はチタン合金の表面処理方法 |
WO2022138924A1 (ja) * | 2020-12-25 | 2022-06-30 | 株式会社エー・アイ・システムプロダクト | チタン又はチタン合金の表面処理方法 |
KR102399423B1 (ko) * | 2021-03-16 | 2022-05-19 | 주식회사 도이프 | 교정용 미니스크류의 제조 및 그 표면처리 방법 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2113834B1 (es) * | 1996-11-12 | 1999-01-01 | Univ Vigo | Metodo de mejora de la osteointegracion de implantes de fijacion osea. |
EP1023910A1 (en) | 1999-01-29 | 2000-08-02 | Institut Straumann AG | Preparation of osteophilic surfaces for metallic prosthetic devices anchorable to bone |
KR100397565B1 (ko) * | 2001-01-16 | 2003-09-13 | 엘지산전 주식회사 | 다기능 하이브리드 개폐기 |
KR20040032297A (ko) * | 2002-10-09 | 2004-04-17 | (주)아미티에 | 생분해성 골접합용 코팅 임플란트 |
KR100546081B1 (ko) | 2003-01-24 | 2006-01-26 | 재단법인서울대학교산학협력재단 | 단백질을 이용한 임플란트용 티타늄의 표면처리 방법 |
ES2350939T3 (es) | 2004-03-10 | 2011-01-28 | Scil Technology Gmbh | Implantes recubiertos, su fabricación y uso de los mismos. |
WO2006056984A2 (en) * | 2004-11-26 | 2006-06-01 | Stentomics Inc. | Chelating and binding chemicals to a medical implant |
US20060159650A1 (en) | 2005-01-14 | 2006-07-20 | Bacterin, Inc. | Composition and method for covalently coupling an antithrombotic substance and a hydrophilic polymer |
DE102007007865A1 (de) * | 2007-02-14 | 2008-08-21 | Jennissen, Herbert, Prof. Dr. | Verfahren zur Herstellung von lagerfähigen Implantaten mit einer ultrahydrophilen Oberfläche |
US20080292779A1 (en) | 2007-05-22 | 2008-11-27 | Mercuri Gregory M | Coating of implants with hyaluronic acid solution |
KR100775537B1 (ko) | 2007-07-19 | 2007-11-28 | (주)오스테오필 | 표면이 개질된 임플란트 제조 방법 및 그에 의해 제조된임플란트 |
CN101269242B (zh) * | 2008-01-16 | 2012-01-04 | 重庆大学 | 转基因细胞覆盖的血管内支架及其制备方法 |
EP2240116B1 (en) | 2008-01-28 | 2015-07-01 | Biomet 3I, LLC | Implant surface with increased hydrophilicity |
KR101248785B1 (ko) | 2012-04-30 | 2013-04-03 | 오스템임플란트 주식회사 | 초친수성을 갖는 티타늄 임플란트, 그 표면처리 및 보관 방법 |
-
2013
- 2013-05-02 KR KR20130049617A patent/KR101404632B1/ko active IP Right Grant
- 2013-09-24 US US14/888,592 patent/US10786602B2/en active Active
- 2013-09-24 WO PCT/KR2013/008525 patent/WO2014178489A1/ko active Application Filing
- 2013-09-24 PT PT138838073T patent/PT2992908T/pt unknown
- 2013-09-24 EP EP13883807.3A patent/EP2992908B1/en active Active
- 2013-09-24 CN CN201380076261.5A patent/CN105339017B/zh active Active
- 2013-09-24 HU HUE13883807A patent/HUE051263T2/hu unknown
- 2013-09-24 ES ES13883807T patent/ES2828063T3/es active Active
- 2013-09-24 DK DK13883807.3T patent/DK2992908T3/da active
- 2013-09-24 JP JP2016511664A patent/JP6383783B2/ja active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210020836A (ko) * | 2019-08-14 | 2021-02-24 | (주)네이처글루텍 | 홍합접착단백질로 코팅된 치과용 임플란트 |
KR102462168B1 (ko) * | 2019-08-14 | 2022-11-02 | (주)네이처글루텍 | 홍합접착단백질로 코팅된 치과용 임플란트 |
Also Published As
Publication number | Publication date |
---|---|
US20160058920A1 (en) | 2016-03-03 |
WO2014178489A1 (ko) | 2014-11-06 |
KR101404632B1 (ko) | 2014-06-27 |
CN105339017A (zh) | 2016-02-17 |
CN105339017B (zh) | 2018-10-02 |
ES2828063T3 (es) | 2021-05-25 |
PT2992908T (pt) | 2020-09-15 |
DK2992908T3 (da) | 2020-09-28 |
HUE051263T2 (hu) | 2021-03-01 |
US10786602B2 (en) | 2020-09-29 |
EP2992908A4 (en) | 2016-12-28 |
EP2992908B1 (en) | 2020-09-02 |
JP2016522026A (ja) | 2016-07-28 |
EP2992908A1 (en) | 2016-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6383783B2 (ja) | インプラントの表面処理方法 | |
ES2481410T3 (es) | Revestimientos salinos bioreabsorbibles de implantes para la protección frente a impurezas orgánicas | |
KR101986089B1 (ko) | 표면에 칼슘을 포함한 임플란트와, 이 표면에 칼슘을 형성하기 위한 임플란트 표면 개질 방법 | |
KR101248785B1 (ko) | 초친수성을 갖는 티타늄 임플란트, 그 표면처리 및 보관 방법 | |
JP2010501212A (ja) | インプラント、特に歯科インプラント | |
Wang | Surface preparation techniques for biomedical applications | |
KR101311990B1 (ko) | 임플란트 표면의 생체활성과 골결합력 및 골융합을 증진시키는 물질이 코팅된 임플란트와 그 제조방법 및 임플란트의 보관 방법 | |
Zhao et al. | Hemocompatibility investigation of the NiTi alloy implanted with tantalum | |
KR101306803B1 (ko) | 임플란트 표면의 생체활성을 증진시키는 유기용매를 이용한 임플란트 및 그 제조방법 | |
KR101304217B1 (ko) | 친수성 보습막이 코팅된 치과용 임플란트 및 그 제조 방법 | |
Shanaghi et al. | Enhanced corrosion resistance and reduced cytotoxicity of the AZ91 Mg alloy by plasma nitriding and a hierarchical structure composed of ciprofloxacin‐loaded polymeric multilayers and calcium phosphate coating | |
JP6095653B2 (ja) | セラミック材料から作られる本体 | |
Guler et al. | The chemical surface evaluation of black and white porous titanium granules and different commercial dental implants with energy‐dispersive x‐ray spectroscopy analysis | |
JP6871309B2 (ja) | チタン又はチタン合金製のボディ上における改善した血液凝固及び/又は細胞接着のためのトポグラフィを調製する方法 | |
KR101271403B1 (ko) | 치과용 임플란트의 친수성 표면 유지를 위한 임플란트 보관방법 | |
JP2010125156A (ja) | 移植材とその製造方法 | |
JP2018521720A5 (ja) | ||
TWI571535B (zh) | 用於金屬植入物表面處理之電解液及利用該電解液進行表面處理之方法 | |
Zhang et al. | Titanium alloy surface coatings using poly (sodium styrene sulfonate) and poly (acrylic acid) | |
GB2503949A (en) | An agent for promoting osseointegration of implants | |
CN116669656A (zh) | 牙种植体 | |
WO2019063711A1 (en) | METHOD FOR PREPARING NANOSTRUCTURES ON A DENTAL IMPLANT | |
AU2018342647A1 (en) | Antithrombotic medical material using nickel titanium alloy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160802 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161101 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170112 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170131 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20170224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170322 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170526 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170530 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170606 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20170908 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180806 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6383783 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |